Naxitamab Biosimilar – Research Grade from ProteoGenix; catalogue PX-TA2534; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The groundbreaking biotech product that is revolutionizing the field of therapeutic targeting. This cutting-edge biosimilar offers a unique and highly effective approach to treating a variety of diseases and conditions.
At its core, Naxitamab Biosimilar – Research Grade is a monoclonal antibody that targets and binds to the GD2 protein, a key therapeutic target in the treatment of neuroblastoma and other types of cancer. This protein is overexpressed in many types of cancer cells, making it an ideal target for targeted therapy.
The main application of Naxitamab Biosimilar – Research Grade is in the treatment of neuroblastoma, a rare and aggressive form of childhood cancer. This biosimilar has shown promising results in clinical trials, with a high success rate in shrinking tumors and improving overall survival rates.
In addition to its use in neuroblastoma, Naxitamab Biosimilar – Research Grade is also being studied for its potential in treating other types of cancer, such as melanoma, osteosarcoma, and small cell lung cancer. Its unique mechanism of action and high specificity make it a promising candidate for a wide range of therapeutic applications.
But what sets Naxitamab Biosimilar – Research Grade apart from other similar products on the market? Its research grade formulation allows for precise and accurate results in experimental settings. This makes it an invaluable tool for researchers and scientists studying the role of GD2 in various diseases and conditions.
With its unparalleled effectiveness and versatility, Naxitamab Biosimilar – Research Grade is quickly becoming the go-to choice for those looking to target GD2 in their research. Its proven track record and potential for future applications make it a must-have for any biotech laboratory.
In summary, Naxitamab Biosimilar – Research Grade is a game-changing biotech product that offers a highly specific and effective approach to therapeutic targeting. Its main application in neuroblastoma, along with its potential for use in other types of cancer, make it a valuable asset in the fight against disease. And with its research grade formulation, it is the ideal choice for scientists and researchers looking to advance their understanding of GD2 and its role in various conditions. Try Naxitamab Biosimilar – Research Grade today and experience the power of targeted therapy.
ProteoGenix catalogue number PX-TA2534. For research use only.
Target: Naxitamab Biosimilar – Research Grade; Host: Mammalian cells; Clonality: Monoclonal antibody; Expression system: Mammalian; Purity: >95% as determined by SDS-PAGE.; Buffer: 0.01M PBS pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
